Traders should monitor upcoming 2026 clinical readouts (e.g., pumitamig, gotistobart, trastuzumab pamirtecan) as key value drivers, but anticipate continued revenue contraction and losses in the near term. The management transition adds execution risk; any delays in oncology pipeline milestones could pressure the stock further.
Price Chart
Executive Summary
BioNTech reported full-year 2025 revenues of €2.87 billion, up 4.3% YoY, but posted a net loss of €1.14 billion (€4.70 diluted loss per share), widening from a €665.3 million loss in 2024. The quarterly revenue declined 23.7% due to lower COVID-19 vaccine demand, and the company issued 2026 revenue guidance of €2.0–2.3 billion, signaling a further decline. Despite a strong cash position of €17.2 billion, the outlook reflects continued transition from pandemic-era revenues to oncology-focused R&D, with multiple late-stage readouts expected in 2026.
Key Financial Metrics
Key Facts
- Full-year 2025 revenue: €2.87 billion (up 4.3% YoY), driven by BMS collaboration revenue in Q3
- Q4 2025 revenue: €907.4 million, down 23.7% YoY due to lower COVID-19 vaccine demand
- Full-year 2025 net loss: €1.14 billion, compared to €665.3 million loss in 2024
- 2026 revenue guidance: €2.0–2.3 billion, implying 19.7%–20.8% YoY decline at midpoint
- Co-founders Ugur Sahin and Özlem Türeci to leave by end of 2026 to lead a new independent mRNA company
- Cash, cash equivalents, and security investments: €17.2 billion as of Dec 31, 2025
Financial Impact
Revenue expected to decline by ~20% in 2026; adjusted R&D expenses to increase to €2.2–2.5 billion despite falling topline
Risk Factors
- Declining revenue and widening losses despite cost discipline
- Management transition risk with co-founders departing by 2026
- Heavy reliance on upcoming clinical data readouts for valuation support
- 2026 guidance implies continued erosion of core vaccine business without near-term commercial offsets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252585 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.90 (−1.98%) |
Sep 14, 2026 18d ago | Press Release | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.90 (−1.98%) |
Aug 28, 2026 5w ago | 6-K | $102.08 $103.76 | ▼ −1.65% | ▼ −1.54% | $96.90 (+5.07%) |
Aug 20, 2026 6w ago | 6-K | $110.89 $111.40 | ▲ +0.46% | ▼ −0.65% | $96.90 (−12.62%) |
Aug 11, 2026 7w ago | Institutional Cluster | $92.80 $92.75 | ▼ −0.05% | ▲ +0.35% | $96.90 (+4.42%) |
Aug 4, 2026 8w ago | 6-K | $91.35 $92.80 | ▼ −1.59% | ▼ −1.69% | $96.90 (−6.08%) |
Aug 3, 2026 8w ago | 6-K | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.90 (+5.04%) |
Aug 3, 2026 8w ago | Press Release | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.90 (+5.04%) |
Jul 29, 2026 9w ago | 6-K | $92.85 $91.19 | ▼ −1.79% | ▼ −5.41% | $96.90 (+4.36%) |
Jun 8, 2026 16w ago | 6-K | $85.50 $90.80 | ▲ +6.20% | ▲ +4.09% | $96.90 (+13.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access